Dr. Ambily K

🚨 Resistant Hypertension: From “Apparent” to “True” — Precision Matters (JAMA 2026) 🔬 Definition & Epidemiology — Not All Resistant HTN is Real Apparent resistant HTN = BP ≥130/80 mm Hg despite ≥3 drugs (ACEi/ARB + CCB + thiazide) at optimal doses ~20% of treated hypertensives fall into this category BUT → True resistant HTN ≈10% only after exclusion of: White-coat effect (~37.5%) Nonadherence (~50%) Secondary causes (~5–25%) 👉 Clinical message: Most “resistant HTN” is pseudo-resistant → diagnosis refinement is critical 🧠 Stepwise Diagnostic Algorithm (High-Yield Clinical Thinking) 1️⃣ Exclude White-Coat Effect Home BP <130/80 OR ABPM <125/75 mm Hg ➡️ Continue monitoring, no overtreatment 2️⃣ Assess Adherence (Underrated Step) Use refill data / drug assays Address: Cost barriers Adverse effects Cognitive issues 3️⃣ Screen Secondary Causes Primary aldosteronism (commonest) CKD, OSA, obesity, drugs (NSAIDs, SNRIs, cocaine) 👉 Only after this → TRUE resistant HTN confirmed ⚠️ Why It Matters (Prognostic Impact) ↑ Cardiovascular mortality risk (absolute ↑ ~10% over 5–10 yrs) Strong association with: Diabetes CKD Obesity Sleep apnea 🧬 Therapeutic Strategy — CME India Algorithmic Pearls 🔹 Step 1: Lifestyle (Foundation Therapy) Sodium <1500 mg/day Weight loss + exercise ≥150 min/week Avoid alcohol, offending drugs Treat OSA 👉 Often neglected but high-yield in India 🔹 Step 2: Optimize Triple Therapy Prefer single-pill combinations (↑ adherence, ↓ SBP ~4 mmHg) Diuretic optimization: Chlorthalidone > thiazide (especially CKD) Add loop diuretic if eGFR <30 🔹 Step 3: Add Mineralocorticoid Receptor Antagonist (MRA) — ⭐ GAME CHANGER Spironolactone 25–50 mg/day ↓ Office SBP: ~13 mmHg ↓ Ambulatory SBP: ~8 mmHg Criteria: eGFR ≥45 ml/min K⁺ ≤4.5 mmol/L 👉 Most effective add-on therapy in resistant HTN 🔹 If Spironolactone Intolerance Amiloride (non-inferior) Eplerenone (less potent, fewer endocrine effects) 🔹 Step 4: Sequential Add-ons β-blockers α1-blockers (doxazosin) Central agents (clonidine) Non-DHP CCB Vasodilators Aprocitentan (dual endothelin antagonist — emerging option) 🔹 Step 5: Device Therapy Renal denervation ↓ Ambulatory SBP ~4.4 mmHg ↓ Office SBP ~6.6 mmHg 👉 For selected refractory cases 💊 Drug Hierarchy (Practical Take-Home) 👉 Best Add-On: ✔️ Spironolactone > all others 👉 Alternatives: ✔️ Amiloride ≈ spironolactone ✔️ Eplerenone (safer endocrine profile) 👉 Less Effective / Add-on: β-blockers, α-blockers, clonidine 👉 New Kid: Aprocitentan (modest effect, fluid retention risk) ⚠️ Adverse Effect Awareness Spironolactone: Hyperkalemia (3–5%) Gynecomastia (~5–9%) Clonidine: Rebound HTN α-blockers: Orthostatic hypotension 🎯 CME INDIA CLINICAL PEARLS 🔴 “Resistant HTN is often diagnostic failure, not therapeutic failure” 🔴 “Half of resistant HTN = nonadherence → always check before escalating” 🔴 “Chlorthalidone + Spironolactone = backbone of resistant HTN therapy” 🔴 “Primary aldosteronism is underdiagnosed → think beyond essential HTN” 🔴 “Single-pill combinations are not convenience—they are outcome modifiers” 🔴 “Renal denervation: modest BP fall but useful in selected refractory cases” 📚 Key Reference (Journal Format) Carey RM, et al. Resistant Hypertension: Diagnosis and Management. JAMA. 2026; doi:10.1001/jama.2026.2846682 jamanetwork.com/journals/jama/…

🛑 2026 Type 2 Diabetes – NICE Update Focus on cardio-renal protection, early SGLT2 use, early Semaglutide in ASCVD, frailty awareness, and safety.

Hyponatremia

#echofirst quiz: When the original diameter of a vessel is reduced to 50% (e.g. coronary artery stenosis), blood flow ml/min is reduced by: A. 20% B. 50% C. 75% D. 87.5% E. 93.75% @Hragy @mmamas1973 @iamritu @CASivaram1 @argulian @ParrasJorge2

NOAC doses in treatment of PE & DVT ● Apixaban and Rivaroxaban start as oral monotherapy (no need for initial heparin). ● Dabigatran and Edoxaban require 5–10 days of parenteral anticoagulation before starting >>> (this is sequential rather than overlapping bridging). Why so?! EHRA practical guide. #cardiology #medicine

🩸 Hemostasis vs Thrombosis: Pathology Summary 🧠DOAC Targets ->Api-Xa-ban / Rivaro-Xa-ban: The name literally tells you the target. Contains "Xa" = Targets Factor Xa. ->Da-bi-gatran: Contains "bi" = Think "2" (Factor II is Thrombin). Dabigatran is a Direct Thrombin Inhibitor. 🧠PT has 2 (less) letters; VII the only factor. It’s short and fast-Extrinsic PTT has 3(many)letters: So many factors are involved-Intrinsic 📌Big Picture: Clotting = Balance ⚖️ Hemostasis = Normal clotting to stop bleeding ✅ Thrombosis = Pathologic clots in vessels ❌ 🩸The body maintains a tight equilibrium between forces: ->Pro-clotting: Intact vessels, platelets 🧱, and the coagulation cascade ⚡. ->Anti-clotting: Natural anticoagulants (Protein C, S, Antithrombin) 🛡️ and fibrinolysis (clot breakdown) ✂️. 🩸The Clotting Process in 3 Steps Step 1: Primary Hemostasis (Platelet Plug 🧱) ->Injury exposes collagen. von Willebrand Factor (vWF) binds it. Platelets adhere, activate, and aggregate to form a temporary plug 🧱. Needs: Adequate functional platelets, vWF. Receptors: GpIb, GpIIb/IIIa. Step 2: Secondary Hemostasis (Coagulation Cascade ⚡) Goal: Generate thrombin ➡️ forms a stable fibrin clot. Key Pathways (Labs): Intrinsic Pathway (PTT): Factors XII ➡️ XI ➡️ IX ➡️ VIII 🔵. Extrinsic Pathway (PT): Tissue Factor (TF) + Factor VII 🔴. Common Pathway: Connects both to activate Thrombin ➡️ forms Fibrin 🟩. 📌Key Concepts: Reactions happen on platelet membranes to increase speed 🚀. Thrombin acts as a feedback amplifier 🔊. Vitamin K is essential to activate Factors II, VII, IX, X 🥬, enabling membrane binding. Step 3: Fibrinolysis (Clot Breakdown ✂️) Plasminogen ➡️ Plasmin, which breaks down the fibrin clot. Too much fibrinolysis = delayed bleeding. 📌Clinical Connections: Bleeding disorders occur from low platelets (petechiae), low vWF (mucosal bleeding), or factor deficiencies (deep bleeding). Thrombosis occurs from low anticoagulants or increased tissue factor. Lab Testing Summary 🧪 🩸PT (Prothrombin Time): Measures the Extrinsic Pathway (Factor VII) 🔴. INR-guided. 🩸PTT (Partial Thromboplastin Time): Measures the Intrinsic Pathway (Factors XII, XI, IX, VIII) 🔵. Heparin-guided. Prolonged PT/PTT: Decision Guide 🟩 PT Normal, PTT Normal: Bleeding still occurring? Think: vWD, Platelet problem, or Factor XIII deficiency (missed by standard labs) 🤔. 🟥 Prolonged PT ONLY: Common causes: Warfarin, early Vitamin K deficiency, liver disease. Targets Factor VII (extrinsic) 🔴, which has the shortest half-life and drops first. 🟦 Prolonged PTT ONLY: Common causes: Heparin, Hemophilia A/B, vWD, Lupus Anticoagulant (prolongs PTT in lab, causes CLOTTING clinically) ⚠️. 🟪 BOTH Prolonged: Indicates a common pathway issue or systemic disorder. Common causes: Liver disease, DIC, advanced Vitamin K deficiency, or deficiencies in X, V, II, fibrinogen. 🩸Diagnostic Approach: Unexplained prolongation? Start with a Mixing Study 🧬. ✅ Corrects (Normalizes): Factor Deficiency (fixes the missing piece). ❌ Fails (Remains prolonged): Inhibitor Present (something is blocking clotting). 🧠Deep Dive into Key Concepts & Diagnoses 📌Natural Anticoagulant Systems 🛡️ Keep clotting in check to prevent thrombosis: 🩸Antithrombin: Inhibits thrombin and Xa; potentiated by heparin. 🩸Protein C/S: Thrombin-activated; inhibits Factors Va, VIIIa. (Needs S as a cofactor). Clinical: Factor V Leiden mutation prevents APC from cleaving Va ➡️ gain of function ➡️ thrombosis ⚠️. Protein C/S deficiency causes venous thrombosis ⚠️. 🩸Fibrinolytic System ✂️ Plasmin breaks down the clot. Deficiencies in inhibitors lead to excessive breakdown and bleeding. 🩸Thrombin Time (TT) Measures fibrinogen ➡️ fibrin conversion. Prolonged by low fibrinogen, heparin, and direct thrombin inhibitors. 📌The "Don't Miss" Diagnoses 🚨 ⚡️Dysfibrinogenemia Normal fibrinogen antigen but low functional fibrinogen ➡️ bleeding OR thrombosis. Autosomal Dominant. Tests functional < antigen. Prolonged TT. Treat with fibrinogen concentrate or cryoprecipitate. ⚡️Factor XIII Deficiency or Acquired Inhibitor Normal PT and PTT! The standard tests MISS it entirely. Causes severe, delayed bleeding and poor wound healing. Test Result: Normal labs, but severe bleeding ➡️ get a CLOT SOLUBILITY test. The unstable clot dissolves in 5M urea or acid. Acquired inhibitors: New-onset bleeding in older patients ➡️ requires immunosuppression. High mortality from treatment infection, not bleeding. 📌Key One-Liners 🧠 Factor VII drops first on Warfarin. Normal labs ≠ normal hemostasis. History > labs for bleeding approach. When PT+PTT are both prolonged, trust history and consider systemic issues or the common pathway. Mixing study always first. Acquired inhibitors ➡️ older patients with new bleeding. 🎯 Master Summary Hemostasis is a balance between platelets 🧱, coagulation ⚡, endothelium, and fibrinolysis ✂️. PT=VII (extrinsic) 🔴. PTT=VIII, IX (intrinsic) 🔵. Missing study separates deficiency vs inhibitor 🧬. Factor XIII deficiency is a normal-lab bleeder missed without solubility test 🚨. #MedTwitter, #MedEd, #Hematology, #Thrombosis, #Thrombophilia, #Hemostasis, #VTE, #Anticoagulation, #Coagulation, #FOAMed @ASH, @Bloodjournal, @NEJM, @HemOncToday @VTEHemostasis, @MedEdHacks, @HematologyNews1 @oncodaily @Hema_News @J_Hematology @realbowtiedoc @IMG_Oncologists @ASH_hematology @ASCOPost

🔥Hyponatremia made simple Dr Ajay Kher: 1️⃣ Serum Osm → hypo vs pseudo 2️⃣ Urine Osm → <100 = polydipsia, >100 = ADH present 3️⃣ Urine Na → <20 = volume depletion, >40 = SIADH 🙇‍♀️Structured thinking = faster diagnosis. #CNSICON2026 @CNSI2026 @VinBhargava @rajdebsaha @drvt87

🚨 Cardio pearls you should never miss 6️⃣ The T wave in the ECG is a story about repolarisation not a random squiggle. When it inverts, something changed in the direction or timing of ventricular recovery. Let’s clear the confusion once for all & understand in depth. 1️⃣ Why is the normal T wave upright? ✔ Purkinje fibers are subendocardial in location. So: Depolarization → Endocardium → Epicardium Repolarization → Epicardium → Endocardium Epicardial cells: 🔻Shorter action potential duration 🔻Larger transient outward K⁺ current (Ito) 🔻Faster phase 3 repolarization Repolarization is a negative wave moving opposite depolarization → vector aligns with QRS. 👉 Upright T wave. 2️⃣ Subendocardial ischemia (early) Inner myocardium + Purkinje network suffer first. Ischemia causes: 🔻ATP depletion 🔻KATP channel opening 🔻Extracellular K⁺ accumulation 🔻Shortened action potential in ischemic zone 🔻Slowed Purkinje conduction ECG: → Tall, symmetric, broad-based T waves (Hyperacute phase) 3️⃣ Transmural ischemia Repolarization sequence reverses abnormally. Vector flips. → Deep, symmetric T-wave inversion Seen in: 🔻Evolving MI 🔻Wellens pattern 🔻Reperfusion Deep + symmetric + territorial + dynamic = ischemia until proven otherwise. 4️⃣ Hyperkalemia Global extracellular K⁺ elevation. ECG: 🔻Narrow, tented T waves 🔻Short QT Sharp, narrow spikes ≠ broad ischemic T waves. 5️⃣ Hypokalemia Delayed repolarization. ECG: 🔻Flat T waves 🔻ST depression 🔻Prominent U waves U waves help differentiate from ischemia. 6️⃣ CNS / Neurogenic T waves Catecholamine surge → myocardial stunning. ECG: 🔻Deep, diffuse T inversions 🔻QT prolongation 🔻Not vascular territory specific Distribution matters. 7️⃣ LVH & Strain Pattern This is not primary ischemia. It’s repolarization abnormality secondary to abnormal depolarization. In LVH: 🔻Increased myocardial mass 🔻Prolonged depolarization 🔻Delayed repolarization in hypertrophied wall ECG: ✔ High-voltage QRS ✔ Downsloping ST depression ✔ Asymmetric T-wave inversion (Usually lateral leads: I, aVL, V5–V6) Key point: Strain T waves are asymmetric, gradual downstroke + rapid return. Ischemic T waves are symmetric. 8️⃣ Cardiomyopathies Hypertrophic cardiomyopathy (HCM) 🔻Deep T inversions (often in precordial leads) 🔻May mimic ischemia 🔻Often associated with large voltages Apical HCM 🔻Giant negative T waves in precordial leads Dilated cardiomyopathy 🔻Nonspecific ST-T changes 🔻Often diffuse Mechanism: Structural remodeling alters repolarization gradients. Not vascular. Not dynamic like ACS. 9️⃣ Final Differentiation Framework ✔ Symmetric + territorial + dynamic → Ischemia ✔ Narrow tented + short QT → Hyperkalemia ✔ Flat T + U waves → Hypokalemia ✔ Diffuse deep T + long QT + neuro event → CNS ✔ High voltage + asymmetric lateral T inversion → LVH strain ✔ Giant precordial inversions + echo changes → HCM ✔ Stable V1–V3 inversion in young → Benign variant T waves reflect: • Repolarization timing • Potassium currents • Myocardial thickness • Conduction sequence • Autonomic tone If you understand vectors + ionic physiology, the ECG becomes logical. Electrophysiology > memorized patterns. (Ref: Marriott’s Practical Electrocardiography; Surawicz & Knilans) #MedTwitter #MedX #ECG #Cardiology

🚨Cardio-emergency pearls you should never miss as a clinician 7️⃣ In hypertensive crisis, the number misleads. The organs tell the real story lets break this down 🟥 HYPERTENSIVE EMERGENCY 🟨 SEVERE BP (NO ORGAN DAMAGE) 🔻1. Definition (Get this right first) Hypertensive crisis = BP ≥180/120 mmHg ⚠️ But classification depends on END-ORGAN DAMAGE, not the number: 🟥 Emergency → Acute target-organ injury 🟨 Severe BP → No injury 👉 Same BP. Completely different management. 🔻2. Terminology update 🟨 “Hypertensive urgency” → ❌ obsolete / discouraged 👉 Why? Misleading → overtreatment → harmful rapid BP lowering ✔️ Use: → Severe asymptomatic hypertension → Severe BP without organ damage 🔻3. Before labeling a crisis - verify BP. Pseudo-elevation is common. ✔️ Correct cuff size ✔️ Repeat after 5 min rest (seated, back supported) ✔️ Measure both arms (>15 mmHg difference → suspect vascular disease) ✔️ Check for: pain, anxiety, full bladder, recent caffeine/nicotine 👉 Many normalize → avoid unnecessary IV therapy 🔻4. Pathophysiology Chronic HTN → right-shifted autoregulation Acute rise → endothelial injury → fibrinoid necrosis + capillary leak → microangiopathy + ischemia Rapid BP fall → hypoperfusion → infarction 🔻5. Target Organ Damage (Defines EMERGENCY) 🧠 Neuro → encephalopathy, stroke, seizures ❤️ Cardiac → ACS, LV failure, pulmonary edema 🧂 Renal → AKI, hematuria/proteinuria 👁 Eye → papilledema, flame hemorrhages 🫀 Vascular → aortic dissection 🤰 Obstetric → preeclampsia/eclampsia 🔻6. MAP : what organs actually care about MAP = DBP + \frac{1}{3}(SBP - DBP) 👉 All targets are based on MAP reduction, not SBP alone. 🟨 SEVERE BP (NO ORGAN DAMAGE) 🔻7. Management (Do less, but do it right) ❌ No IV antihypertensives ❌ No rapid BP reduction ✔️ Start/adjust oral therapy ✔️ Identify triggers (pain, NSAIDs, steroids, non-adherence) ✔️ Reinforce compliance ✔️ Follow-up in 24–72 hrs ⚠️ Rapid lowering here → stroke / syncope risk 🟥 HYPERTENSIVE EMERGENCY 🔻8. Core principle - Controlled reduction: • 1st hour → ↓ MAP ≤25% • Next 2–6 hrs → ~160/100–110 mmHg (slight correction) • 24–48 hrs → gradual normalization ❌ Never normalize immediately 🔻9. Why this matters Chronic HTN → shifted autoregulation Rapid drop → hypoperfusion → → Stroke → MI → AKI 🔻10. Condition-specific targets 🫀 Aortic dissection → SBP <120 + HR <60 (within minutes) → IV beta-blocker FIRST (then vasodilator) 🧠 Ischemic stroke → No thrombolysis: allow ≤220/120 → Thrombolysis:  Before: <185/110  After: <180/105 🧠 ICH → Target SBP ≈ 140 → Avoid <130 💦Pulmonary edema → IV nitroglycerin + diuretics 🤰 Preeclampsia/eclampsia → Labetalol / Hydralazine → MgSO₄ (seizure prophylaxis) sympathomimetic → ❌ Avoid pure β-blockers → Use benzodiazepines + vasodilators 🔻11. IV drugs (Know your weapons) ✔️ Nicardipine ✔️ Labetalol ✔️ Esmolol ✔️ Clevidipine ✔️ Nitroglycerin ⚠️ Nitroprusside → last resort (cyanide toxicity & sudden hypotension) 🔻12. Investigations (Don’t miss organ damage) 🧪 Labs: CBC, creatinine, electrolytes Troponin, LDH Urinalysis (protein/hematuria) Imaging: ECG CXR CT brain (if neuro signs) Echo (if cardiac involvement) 🔻BEDSIDE CLINICAL EXAM (MUST DO) General Mental status → encephalopathy? Seizures / confusion Vitals BP in BOTH arms Pulse deficit → Aortic dissection Eye (Fundoscopy) Papilledema → emergency Hemorrhages/exudates Cardiac S3 → LV failure New murmur → dissection (AR) Respiratory • Crackles → pulmonary edema Neuro • Focal deficits → stroke Peripheral • Weak/absent pulses → vascular cause 🔻14. Pitfalls (Exam + real life traps) ❌ Treating numbers blindly ❌ Overcorrection (>25% drop early) ❌ Missing aortic dissection ❌ Giving IV drugs in non-emergency ❌ Not doing fundoscopy #MedTwitter #MedX #Cardiology

When to treat high blood pressure: Summary of the 2025 AHA/ACC hypertension guidelines 🚨 ahajournals.org/doi/10.1161/HY…

AACE 2026 – Type 2 Diabetes Algorithm Update 🔹 Pearl 1 — Diabetes care is no longer glucose-centric AACE 2026 shifts the paradigm from HbA1c control to comprehensive cardiometabolic risk reduction. 🔹 Pearl 2 — Obesity is now a primary therapeutic target Weight management is not adjunct—it is central to both prevention and treatment of T2D. 🔹 Pearl 3 — Treat adiposity early, not late Early use of anti-obesity pharmacotherapy (e.g., GLP-1 RA / dual incretins) is encouraged to alter disease trajectory. 🔹 Pearl 4 — Complications drive therapy selection Choice of drugs should be guided by ASCVD, CKD, HF, and obesity—not just HbA1c level. 🔹 Pearl 5 — GLP-1 RA and SGLT2 inhibitors remain foundational These agents are prioritized for both glycemic control and organ protection (heart, kidney, weight). 🔹 Pearl 6 — “Right diagnosis” precedes “right treatment” AACE introduces emphasis on evaluating diabetes type—avoid mislabeling all patients as T2D. 🔹 Pearl 7 — Prediabetes is a treatable disease state Aggressive lifestyle + weight-focused interventions can delay or prevent progression. 🔹 Pearl 8 — Dyslipidemia management is integral, not optional LDL-C and non-HDL targets are critical components of diabetes care. 🔹 Pearl 9 — Hypertension control is part of diabetes therapy Blood pressure optimization is a core pillar of reducing macrovascular risk. 🔹 Pearl 10 — Personalization is the new standard Therapy must be individualized based on phenotype: obesity, sarcopenia, CV risk, renal status, and age. 🔹 Pearl 11 — Move from “treat to target” to “treat to outcome” Focus shifts toward reducing events (MACE, CKD progression, mortality), not just numbers. 🔹 Pearl 12 — Diabetes is a multisystem disease Management must integrate metabolic, cardiovascular, renal, and functional domains. 🔶 CME INDIA One-Line Takeaway “AACE 2026 redefines diabetes care: treat weight early, reduce risk aggressively, and individualize therapy beyond glucose.” endocrinepractice.org/article/S1530-…

😎Key indications for CKRT in the ICU By Dr Kanav Anand #CNSICON2026

1/9 The 2026 ACC/AHA Dyslipidemia Guidelines are officially here! Replacing the 2018 guidelines, these new updates bring major shifts in risk assessment, novel lipid markers, and cholesterol targets. Here are the most salient features you need to know. 🧵👇 #Cardiology #MedTwitter

CKD doesn’t have to stop your journey. Vaccinate. Plan ahead. Travel safely. 🛡️✈️ #KidneyHealth #Dialysis #CKD #WKD2026 #KidneyHealthForAll #ISNCares #ISNIndia Infographic by @DrAkshayaJ @worldkidneyday @arvindcanchi @drshyambansal @taruna_pahuja @KKNephBytes @YashenduSarda

🦀Management of MGRS academic.oup.com/ndt/article/41… @NDTsocial @hjanders_hans

Proposed framework for diuretic management in patients with reduced kidney function and acute heart failure (HF) ca. 2026 from @goKDIGO @Kidney_Int #Nephpearls #Cardiorenal 📌 This algorithm provides a list of what to look for when you're assessing optimal response to a diuretic regimen 👉 pubmed.ncbi.nlm.nih.gov/41791738/

😎 Nephrotic syndrome management in era of newer autoantibodies academic.oup.com/ndt/article/41… @NDTsocial @hjanders_hans

Join this global initiative, CRESCENDO, which collects data on patients with crescentic lesions on their kidney biopsy. Reach out to one of the team members. 6 continents, over 100 centers have registered already! academic.oup.com/ckj/advance-ar… @AnnetteBruchfe1 and Vanja Ivkovic

90% of students “read” research papers and still can’t explain them….This is the method I use anytime I lead a Journal Club. I can tell in 30 seconds if you actually understood a research paper…. Most people don’t…. They “read” it… Then they can’t explain the question, the method, or the point. Here’s the reading method researchers are trained to use: The Three-Pass Method. ⸻ ★ PASS 1 (5–10 minutes) Get the map, not the details Read only: → Title → Abstract + intro → Section headings → Conclusion → References (quick glance) By the end, you should be able to say: ↳ What kind of paper is this ↳ What problem is it solving ↳ What are the main contributions ↳ Do the assumptions seem reasonable ↳ Is it worth your time If the answer is “no,” stop here. That’s not quitting. That’s focus. ⸻ ★ PASS 2 (up to 1 hour) Understand the argument Now read with a pen. Your job is to track: → What claim are they making → What evidence supports it → What figures/graphs prove it Study the visuals like your reputation depends on it: ↳ Are axes labeled ↳ Are error bars shown ↳ Do the results actually justify the conclusion At the end of pass 2, you should be able to explain the paper out loud to a friend. No notes. If you can’t, you don’t own it yet. ⸻ ★ PASS 3 (the “real researcher” pass) Rebuild the paper in your head This is the move that separates “I read it” from “I understand it.” Try to recreate the work mentally: → Why this method and not another → What assumptions are hiding in plain sight → What would break if one assumption fails → What would you change if you ran the study By the end, you should be able to reconstruct the whole paper from memory, including strengths and weak spots. ⸻ 💬 What trips you up the most when reading papers? ♻️ Repost if you know someone drowning in PDFs.